NCT06396026 - A Study of Efficacy and Safety of TLL-018 in CSU Participants | Biotech Hunter

Enrollment

436

Participants

Timeline

Start Date

December 24, 2024

Primary Completion Date

March 30, 2026

Study Completion Date

December 30, 2027

Conditions

Chronic Spontaneous Urticaria

Interventions

DRUG

TLL-018 tablets

Oral TLL-018 tablets taken orally 1 pieces BlD for 52 weeks

DRUG

Placebo tablets

Oral Placebo tablets taken orally 1 pieces BlD for 12 weeks and then Oral TLL-018 tablets taken orally 1 pieces BlD for 40 weeks.

Trial Locations (1)

RECRUITING

Hospital for Skin Diseases, Institute of Dermatology, Chinese Academy of Medical Sciences, Nanjing